Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome Alachkar, Houda , Santhanam, Ramasamy , Maharry, Kati ... - - J. Clin. Invest - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-9621
Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment An, Ming-Wen , Mandrekar, Sumithra J. , Edelman, Martin J. ... - - Contemp Clin Trials - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-30203
Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance) Barton, Debra L. , Thanarajasingam, Gita , Sloan, Jeff A. ... - - Cancer - 2014 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance) Barton, Debra , Dockter, Travis , Atherton, Pamela , Lester, Joanne ... - CANS - - 2014 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 Becker, Heiko , Maharry, Kati , Mrózek, Krzysztof , Volinia, Stefano ... - - Leukemia - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103) Beumer, Jan H. , Owzar, Kouros , Lewis, Lionel D. , Jiang, Chen ... - - Cancer Chemother. Pharmacol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - PPP - C19808 , CALGB-100103 , CALGB-10503
Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy Beutler, Andreas S. , Kulkarni, Amit A. , Kanwar, Rahul ... - - Ann. Neurol. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - N08C1 , N08CA
Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial Boughey, Judy C. , McCall, Linda M. , Ballman, Karla V. ... - - Ann. Surg. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance) Burstein, Harold J. , Cirrincione, Constance T. , Barry, William T. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial Cheng, H , Ballman, K , Vassilakopoulou, M , Dueck, A C ... - - Br. J. Cancer - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Polygenic Inheritance of Paclitaxel-Induced Sensory Peripheral Neuropathy Driven by Axon Outgrowth Gene Sets in CALGB 40101 (Alliance) Chhibber, Aparna , Mefford, Joel , Stahl, Eli A. ... - - Pharmacogenomics J. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101
Methodological Considerations in the Design and Implementation of Clinical Trials Cirrincione, Constance T. , Lavoie Smith, Ellen M. ... - - Semin Oncol Nurs - 2014 Manuscript - No-Endpoint Endpoint - Other Analysis - Onc Nursing - Pilot
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657) Clark, Amy S , Chen, Jinbo , Kapoor, Shiv , Friedman, Claire ... - - Cancer Med - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Corless, Christopher L. , Ballman, Karla V. , Antonescu, Cristina R. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Cureton, Elizabeth L. , Yau, Christina , Alvarado, Michael D. ... - - Ann. Surg. Oncol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103
Clinical impact of ABL1 kinase and IKZF1 mutations in adults with Philadelphia chromosome-positive (PH+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB 10001 and 9665 (Alliance) DeBoer, Rebecca , Mulkey, Flora , Koval, Gregory , Wetzler, Meir ... - EHA - Haematologica - 2014 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10001 , CALGB-9665
Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis Ding, Wei , Shanafelt, Tait D. , Lesnick, Connie E. ... - - Br. J. Haematol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - N1087
Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma Dronca, Roxana S. , Allred, Jacob B. , Perez, Domingo G. ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0675
CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D
NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901 Faul, Leigh Anne , Luta, Gheorghe , Sheppard, Vanessa ... - - J Cancer Surviv - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer Fernando, Hiran C. , Landreneau, Rodney J. , Mandrekar, Sumithra J. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) Fuchs, Michael A. , Sato, Kaori , Niedzwiecki, Donna , Ye, Xing ... - - PLoS ONE - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902) Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874
Expression and prognostic impact of lncRNAs in acute myeloid leukemia Garzon, Ramiro , Volinia, Stefano , Papaioannou, Dimitrios ... - - Proc. Natl. Acad. Sci. U.S.A - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202
Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies Goetz, Matthew P. , Sun, James X. , Suman, Vera J. , Silva, Grace O. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 Gonsalves, Wilson I. , Mahoney, Michelle R. , Sargent, Daniel J. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0147
Accuracy of FDG-PET within the clinical practice of the ACOSOG Z4031 trial to diagnose clinical stage I NSCLC Grogan, Eric L. , Deppen, Stephen A. , Ballman, Karla V. ... - - Ann. Thorac. Surg. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. Halabi, Susan , Kelly, William Kevin , Zhou, Haojin ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - CALGB-90401 , S9916
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer Halabi, Susan , Lin, Chen-Yen , Kelly, W. Kevin , Fizazi, Karim S. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC) Halabi, Susan , Rini, Brian , Escudier, Bernard , Stadler, Walter M. ... - - Cancer - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90206
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance). Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Breast - N0733
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance). Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80203
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML Havelange, Violaine , Ranganathan, Parvathi , Geyer, Susan ... - - Blood - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , C9720 , CALGB-10201 , CALGB-8923 , CALGB-9420
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer Heist, Rebecca S. , Wang, Xiaofei , Hodgson, Lydia ... - - J Thorac Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704
A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-60404 , CALGB-90401
Public Health and Cooperative Group Partnership: A Colorectal Cancer Educational Intervention for Breast Cancer Survivors Homan ... - - Semin Oncol Nurs - 2014 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Onc Nursing - A21_011
Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0147
Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603 Iglesia, Michael D. , Vincent, Benjamin G. , Serody, Jonathan S. ... - SABCS - Cancer Res. - 2014 Abstract - Secondary Endpoint - Comprehensive Analysis - Breast - CALGB-40601 , CALGB-40603
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Inwards, D J , Fishkin, P A , LaPlant, B R , Drake, M T , Kurtin, P J ... - - Ann. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N078D
Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial Jagsi, Reshma , Chadha, Manjeet , Moni, Janaki , Ballman, Karla ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Joensuu, Heikki , Eriksson, Mikael , Hall, Kirsten Sundby ... - - Cancer - 2014 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - ACOSOG-Z9001
Regional Differences In Breast Cancer Biomarkers In American Indian And Alaska Native Women Kaur, Judith S , Vierkant, Robert A. , Hobday, Timothy ... - - Cancer Epidemiol. Biomarkers Prev. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Disparities - NCCTG-97-95-51
Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance) Klepin, Heidi D. , Pitcher, Brandelyn N. , Ballman, Karla V. ... - - J Oncol Pract - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907 , CALGB-361004
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). Klepin, Heidi D. , Ritchie, Ellen K. , Sanford, Ben L. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Older Adult - CALGB-361006
Nursing contributions in Community Clinical Oncology Research Programs. Klinger, Kathy , Figueras, Cesar , Beney, Kathleen M , Armer, Jane M ... - - Semin Oncol Nurs - 2014 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Onc Nursing -
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206 Kluger, Harriet M. , Halabi, Susan , Solomon, Nicole C ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90206
Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission Kolitz, Jonathan E. , George, Stephen L. , Benson, Don M. ... - - Cancer - 2014 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Leukemia - CALGB-19808
Nursing's presence in the changing cooperative group setting. Kottschade, Lisa A , Bell, Jennifer , Klinger, Kathy ... - - Semin Oncol Nurs - 2014 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Onc Nursing -
A Comparison of Outcomes between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance) Kutny, Matthew A. , Geyer, Susan , Laumann, Kristina M ... - ASH - Blood - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C9710
Effect of young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia: North American Intergroup Study CALGB 9710 (Alliance) Kutny, Matthew A. , Gregory, John , Geyer, Susan , Laumann, Kristina ... - ASH - Blood - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C9710
Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens Lamont, E. B. ... - - Med Care - 2014 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Health Outcome - CALGB-9344 , CALGB-9730 , CALGB-9235 , CALGB-9732 , CALGB-80203 , CALGB-89803
Generalizability of Trial Results to Elderly Medicare Patients with Advanced Solid Tumors (Alliance 70802) Lamont, Elizabeth B. , Schilsky, Richard L. , He, Yulei , Muss, Hyman ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-70802
Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802) Lamont, Elizabeth B. , Yu, Menggang , He, Yulei , Saltz, Leonard ... - - J Geriatr Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-70802
NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study Leal, Alexis D. , Qin, Rui , Atherton, Pamela J. , Haluska, Paul ... - - Cancer - 2014 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08CA
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Head and Neck Radiotherapy With or Without Chemotherapy: A Phase III, Randomized, Double-Blind Trial (NCCTG-N09C6 [Alliance]) Leenstra, James L. , Miller, Robert C. , Qin, Rui ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N09C6
CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon Lenz, H. , Niedzwiecki, D. , Innocenti, F. , Blanke, C. , Mahoney, M. ... - ESMO - Ann. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - C80405
A mentored cooperative group pilot study: atrophic vaginitis. Lester, Joanne L , Jarvis, Chandler , Bartholomew, Deborah ... - - Semin Oncol Nurs - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Onc Nursing - NCT02150525
The nurse liaison role in the cooperative group setting. Levy, Sharon , Klinger, Kathy , Galinsky, Ilene , DeKrey, Wanda ... - - Semin Oncol Nurs - 2014 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Onc Nursing -
Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial Liu, M.C. , Rack, B. , Dueck, A.C. , Hillman, D.W. , Campion, M.B. ... - SABCS - Cancer Res. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D
Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Lockhart, A C , Reed, C E , Decker, P A , Meyers, B F , Ferguson, M K ... - - Ann. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z4051
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance) Loprinzi, Charles L. , Qin, Rui , Dakhil, Shaker R. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08CB
Adding the KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB study 10801 (Alliance) Marcucci, Guido , Geyer, Susan , Zhao, John , Caroll, Andrew J ... - ASH - Blood - 2014 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10801
Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score Marcucci, Guido , Yan, Pearlly , Maharry, Kati , Frankhouser, David ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-9420 , CALGB-9720 , CALGB-9621 , CALGB-19808
CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma Martin, Peter , Jung, Sin-Ho , Johnson, Jeffrey L. , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50803
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy Maurer, Matthew J. , Ghesquières, Hervé , Jais, Jean-Philippe ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - N0489
Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study McCullough, Ann E. , Dell'Orto, Patrizia , Reinholz, Monica M. ... - - Breast Cancer Res. Treat. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N063D
Primary and Secondary Endpoint Analysis of N08C9 (Alliance)- A Phase III Randomized Trial of Sulfasalazine versus Placebo in the Prevention of Acute Radiation Enteritis Miller, R. C. , Petereit, D. G. , Sloan, J. A. , Liu, H. ... - ASTRO - INT J RADIAT BIOL - 2014 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N08C9
A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621 Molina, Julian R. , Foster, Nathan R. , Reungwetwattana, Thanyanan ... - - Lung Cancer - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0621
Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim. Moukharskaya, Julia , Abrams, Deborah Michelle , Khan, Farrah B. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCT01311336
Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer Ng, Kimmie , Meyerhardt, Jeffrey A. , Chan, Andrew T. , Sato, Kaori ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original Endpoint - Long-Term-Followup Analysis - Prevention - C89803
Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer Northfelt, DW , Allred, JB , Liu, H , Hobday, TJ , Rodacker, MW ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0437
Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831 Norton, Nadine , Olson, Rebecca M. , Pegram, Mark , Tenner, Kathleen ... - - Cancer Immunol Res - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
VATS Lobectomy Has Better Peri-operative Outcomes than Open Lobectomy: Ancillary Analysis of CALGB 140202 (Alliance) Nwogu, C. E. , D’cunha, J. , Pang, H. , Gu, L. , Wang, X. ... - STS - - 2014 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-140202
Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance) Pachman, Deirdre R. , Qin, Rui , Seisler, Drew K. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N08CB
NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C2
A Randomized Trial of Diet in Men with Early Stage Prostate Cancer on Active Surveillance: Rationale and Design of the Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - Contemp Clin Trials - 2014 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Prevention - CALGB-70807
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401 , CALGB-60404
MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial Pavelitz, Thomas , Renfro, Lindsay , Foster, Nathan R. ... - - PLoS ONE - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Perez, Edith A. , Romond, Edward H. , Suman, Vera J. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Comprehensive Analysis - Breast - N9831
Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Piccart-Gebhart, Martine J. , Holmes, Andrew Peter , Baselga, Jose ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Breast - N063D
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype Poiré, Xavier , Moser, Barry K. , Gallagher, Robert E. ... - - Leuk. Lymphoma - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-9710
Predicting response and survival in chemotherapy-treated triple-negative breast cancer Prat, A , Lluch, A , Albanell, J , Barry, W T , Fan, C , Chacón, J I ... - - Br. J. Cancer - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - C9741 , CALGB-159905
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002 Rizzieri, David A. , Johnson, Jeffrey L. , Byrd, John C. ... - - Br. J. Haematol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10002
Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer Roman, Michael A. , Koelwyn, Graeme J. , Eves, Neil D. ... - - Respirology - 2014 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9238
Prognostic and Predictive Biomarkers for ACT (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-NSCLC): LACE-Bio Seymour, L. K. , Teuff, G. Le , Tsao, M. , Brambilla, E. ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-150802 , CALGB-9633
Association study of the let-7 miRNA-complementary site variant in the 3’ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial) Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact. Shah, Mithun Vinod , Wiktor, Anne E. , Meyer, Reid G. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901 Sheppard, Vanessa B. , Faul, Leigh Anne , Luta, George ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer Shiovitz, Stacey , Bertagnolli, Monica M. , Renfro, Lindsay A. ... - - Gastroenterology - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans Shofer, Scott , Beyea, Matthew , Li, Sufeng , Bastian, Lori A ... - - BMJ Open Respir Res - 2014 Manuscript - Primary Endpoint - Primary Analysis - Prevention - NCT01038492
Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance) Shulman, Lawrence N. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-40101
A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results From ACOSOG (Alliance) Z1072 Simmons, Rache , Ballman, Karla , Cox, Charles , Carp, Ned ... - ASBrS - Ann. Surg. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1072
Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales. Singh, Jasvinder A , Locke, Dona E , Satele, Daniel ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Health Outcome - 954651 , NCCTG-95-20-53 , NCCTG-95-24-52 , 959204 , NCCTG-964251 , 979202 , NCCTG-98-24-52 , NCCTG-98-72-51 , NCCTG-98-72-52 , NCCTG-959257 , NCCTG-989251 , NCCTG-969256 , NCCTG-971151 , NCCTG-979251 , NCCTG-979253
Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales Singh, Jasvinder A , Satele, Daniel , Pattabasavaiah, Suneetha ... - - Health Qual Life Outcomes - 2014 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Health Outcome - NCCTG-95-20-53 , 954651 , 959204 , NCCTG-95-24-52 , NCCTG-964251 , 979202 , NCCTG-97-24-51 , NCCTG-98-24-52 , NCCTG-98-72-51 , NCCTG-959257 , NCCTG-98-72-52 , NCCTG-989251 , NCCTG-969256 , NCCTG-971151 , NCCTG-979251 , NCCTG-979253
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. Sinicrope, Frank A. , Yoon, Harry H. , Mahoney, Michelle R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy. Sloan, Jeff A. , Major, Brittny , Novotny, Paul J. , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - NCCTG-89-20-52
Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials Sloan, Jeff A. , Sargent, Daniel J. , Novotny, Paul J. ... - - J Pain Symptom Manage - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - NCCTG-89-20-52
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance) Smith, Matthew R. , Halabi, Susan , Ryan, Charles J. , Hussain, Arif ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90202
Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: ALLIANCE A051201 and A051202 Smith, Sonali M. , Pitcher, Brandelyn N. , Jung, Sin-Ho ... - ASH - Blood - 2014 Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - A051201 , A051202
Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. Socinski, Mark A. , Wang, Xiaofei F. , Baggstrom, Maria Quintos ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607
Switch Maintenance with Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-controlled Phase III Trial Socinski, Mark A. , Wang, Xiaofei F. , Baggstrom, Maria Quintos ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2014 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607
Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance) Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - C10403 , CALGB-10403
Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (Alliance) trial Su, Stacey , Scott, Walter J , Allen, Mark S , Darling, Gail E ... - - J. Thorac. Cardiovasc. Surg. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab Van Loon, Katherine , Espinoza, Anne M. , Fogelman, David R. ... - - Pancreas - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N034A
25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance) Van Loon, Katherine , Owzar, Kouros , Jiang, Chen , Kindler, Hedy L. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-151006 , CALGB-80303
CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy Venook, A. , Niedzwiecki, D. , Lenz, H. , Mahoney, M. , Innocenti, F. ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-80405
CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the colon Venook, A. , Niedzwiecki, D. , Lenz, H.J. , Innocenti, F. ... - ESMO GI - Ann. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80405
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Venook, Alan P. , Niedzwiecki, Donna , Lenz, Heinz-Josef ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80405
CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy Vij, Ravi , Hars, Vera , Shea, Thomas , Hoke, Eva , Blum, William ... - ASH - Blood - 2014 Abstract - Secondary Endpoint - Primary Analysis - Transplant - CALGB-100801
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance) Wang, Xiaofeng , Owzar, Kouros , Gupta, Pankaj , Larson, Richard A ... - - Br J Clin Pharmacol - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-10105
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification Wetzler, Meir , Mrózek, Krzysztof , Kohlschmidt, Jessica ... - - Haematologica - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8221 , C8525 , C9720 , CALGB-10201 , CALGB-8923
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance) Wetzler, Meir , Watson, Dorothy , Stock, Wendy , Koval, Gregory ... - - Haematologica - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy Whitman, Susan P. , Kohlschmidt, Jessica , Maharry, Kati ... - - Leukemia - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8525 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9720 , CALGB-10201 , CALGB-19808
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer Wolpin, Brian M. , Rizzato, Cosmeri , Kraft, Peter ... - - Nat. Genet. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - C80303
Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]). Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance) Yoon, Harry H. , Tougeron, David , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
